Teva Said to Weigh Options for Branded Generics to Reduce Debt


Teva Pharmaceutical Industries Ltd. is weighing options including a sale of its branded generics drugs business as it works to reduce debt, according to people familiar with the matter. The business could be valued at several billion dollars, and Teva may also consider spinning off the unit, the people said, asking not to be identified because the deliberations are private.



from Biotech News